Overview

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-30

Target enrollment:

Participant gender:

Summary

This study will enroll patients with locally advanced non-small cell lung cancer (NSCLC). Patients will receive neoadjuvant chemotherapy combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, followed by concurrent chemoradiotherapy, and finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1. The study aims to evaluate the efficacy and safety of this treatment regimen.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Neoadjuvant Therapy
Radiotherapy